What question did this study set out to answer?

To investigate if female sex increases the risk of cardiac arrhythmias from erythromycin and correlate findings with QT-response in rabbit hearts.

November 25, 1998JAMA

Cardiac Actions of Erythromycin

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Erythromycin-associated cardiac arrhythmias (n=346). Intervention: Female sex vs. Male sex. Primary outcome: Life-threatening ventricular arrhythmias and deaths directly related to intravenous erythromycin lactobionate (p=.03).

View Full Paper

Ask AI

Bookmark

Key result

Female sex was associated with a significantly higher proportion of life-threatening ventricular arrhythmias and deaths related to intravenous erythromycin compared to male sex (67% vs 33%; P=0.03).

Authors

MDMilou‐Daniel DriciUniversité Côte d'Azur BKBjörn C. KnollmannElectrophysiology WWWen-Xiu WangPeking University

Discussion

Member takes

Implication

Suggests heightened proarrhythmic susceptibility to erythromycin in women; leaves open whether sex-specific dosing.

Key Points

To investigate if female sex increases the risk of cardiac arrhythmias from erythromycin and correlate findings with QT-response in rabbit hearts.
FDA MEDWATCH database analysis of cardiac arrhythmia cases associated with erythromycin from 1970 to 1996.
In vitro experiment measuring QT-prolongation in isolated perfused rabbit hearts after erythromycin administration.
346 reported cases of cardiac arrhythmias linked to erythromycin, with a higher incidence in females (58%).
49 cases linked to life-threatening arrhythmias; 67% were women and 33% were men (P=.03).
QT-prolongation was significantly greater in female rabbit hearts (11.8%) than in male hearts (6.9%; P=.03).

Study Design

Type

Observational (n=346)

PICO

Population

346 cases of erythromycin-associated cardiac arrhythmias reported to the FDA MEDWATCH database between 1970 and 1996.

Exposure / Comparator

Female sex vs Male sex

Primary Outcome

Life-threatening ventricular arrhythmias and deaths directly related to intravenous erythromycin lactobionate, p=.03

Main Result

Absolute Event Rate: 67% vs 33%

p-value: p=.03

Cite This Study

Drici et al. (1998) conducted an observational in Erythromycin-associated cardiac arrhythmias (n=346). Female sex vs. Male sex was evaluated on Life-threatening ventricular arrhythmias and deaths directly related to intravenous erythromycin lactobionate (p=.03). Female sex was associated with a significantly higher proportion of life-threatening ventricular arrhythmias and deaths related to intravenous erythromycin compared to male sex (67% vs 33%; P=0.03).

synapsesocial.com/papers/6a238477b7e293e61ca5e5e8 https://doi.org/10.1001/jama.280.20.1774

View Full Paper

Ask AI

Bookmark

Cardiac Actions of Erythromycin

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Cardiac Actions of Erythromycin

Discussion

Member takes

Implication

Key Points

Study Design

PICO

Main Result

Cite This Study

Also Consider

Also Consider